在炎症性肠道疾病中地中海饮食是否准备好进入黄金时代?
Lihi Godny1,2, Iris Dotan1,3
1Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, 49100, Israel.
Journal of the Canadian Association of Gastroenterology
|February 5, 2024
概括
地中海饮食 (MED) 可能有助于预防和管理炎症性肠病 (IBD). 坚持MED与更好的临床结果,减少炎症和改善IBD患者的生活质量有关.
科学领域:
- 胃肠病学和营养科学 胃肠病学和营养科学
- 饮食对慢性疾病的影响
背景情况:
- 全球炎症性肠道疾病 (IBD) 发病率上升,包括克罗恩病 (CD) 和性结肠炎 (UC),表明环境因素.
- 西方化的饮食有所影响,而地中海饮食 (MED) 显示出对IBD的潜在益处.
研究的目的:
- 审查关于地中海饮食在IBD预防和管理中的作用的证据.
主要方法:
- 现有流行病学和临床研究的叙述性审查.
- 专注于证据,将MED与IBD发展,临床过程和患者结果联系起来.
主要成果:
- 流行病学研究表明,MED坚持和CD发展之间存在相反的关联.
- 医学医学与活跃CD的临床改善,UC的炎症减少,改善生活质量和IBD患者的死亡率降低有关.
- 机制包括促进有益的肠道微生物群,通过多和脂肪产生抗炎作用,以及氧化应激调节.
结论:
- 目前的证据支持将地中海饮食纳入IBD护理.
- 需要进一步的研究来评估MED在特定IBD表型中的疗效.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


